GE HealthCare Technologies Prepares for Upcoming Earnings Report

Headquartered in Chicago, Illinois, GE HealthCare Technologies Inc. (GEHC) specializes in developing, manufacturing, and marketing products, services, and digital solutions for diagnosing, treating, and monitoring patients across the United States, Canada, and worldwide. The company boasts a market capitalization of $28.7 billion and operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

Upcoming Earnings Expectations

GE HealthCare is set to report its Q1 earnings on Tuesday, April 29. Analysts forecast that GEHC will announce an earnings per share (EPS) of $0.91, marking a 1.1% increase from the $0.90 reported in the same quarter last year. Notably, the company has either met or exceeded analysts’ earnings estimates for the past four quarters. In the most recent quarter, GEHC achieved an adjusted EPS of $1.45, exceeding expectations by 15.1%, driven by strong performance in its Advanced Visualization Solutions and Pharmaceutical Diagnostics segments.

Future Financial Projections

Looking ahead to fiscal year 2025, analysts project an adjusted EPS of $4.68 for GEHC, representing a 4.2% increase from $4.49 in fiscal year 2024. Further growth is anticipated in fiscal 2026, with adjusted EPS expected to rise 11.1% to $5.20 year-over-year.

Recent Stock Performance

Over the past year, GEHC shares have declined by 25.4%, underperforming the S&P 500 Index’s gain of 5.5% and the Health Care Select Sector SPDR Fund’s (XLV) slight decrease during the same period.

On April 6, GE HealthCare’s stock plummeted nearly 16%, becoming the largest percentage loser on the S&P 500. This drop followed China’s initiation of an anti-dumping investigation into imports of a type of medical X-ray tube from the United States.

Analyst Ratings and Price Projections

The consensus view on GEHC remains cautiously optimistic, with an overall “Moderate Buy” rating. Among the 18 analysts covering the stock, 13 recommend a “Strong Buy,” four advise a “Hold,” and one recommends a “Strong Sell.” The average price target stands at $100.61, suggesting a potential upside of 56.3% from current levels.

On the date of publication, Kritika Sarmah did not hold (either directly or indirectly) any positions in the securities mentioned in this article. All information and data in this article are provided for informational purposes. For more information, please view the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.